Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond

被引：19

作者：

Ansell, Stephen M. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2016年 / 91卷 / 01期

关键词：

STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; PHASE-II; DISEASE; ABVD; HYBRID; ACTIVATION; CONJUGATE; THERAPY; TRIALS;

D O I：

10.1002/ajh.24226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hodgkin lymphoma is a rare lymphoid malignancy affecting similar to 9,200 new patients in the United States annually. Progress in the management of this disease over the past 50 years has been remarkable and the prognosis of this malignancy has changed from a uniformly fatal process to one in which the vast majority of patients are expected to be cured. This remarkable progress has been due to the use of combination approaches incorporating chemotherapy and radiation therapy, and now more recently antibody-drug conjugates and immune checkpoint inhibitors. The goal for the future is to develop treatment combinations that successfully treat all patients and markedly decrease the long-term side effects. (c) 2015 Wiley Periodicals, Inc.

引用

页码：109 / 112

页数：4

共 32 条

[11] Forero-Torres A, 2015, 2015 ASCO ANN M JUN
[12] cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
Francisco, JA
Cerveny, CG
Meyer, DL
Mixan, BJ
Klussman, K
Chace, DF
Rejniak, SX
Gordon, KA
DeBlanc, R
Toki, BE
Law, CL
Doronina, SO
Siegall, CB
Senter, PD
Wahl, AF
[J]. BLOOD, 2003, 102 (04) : 1458 - 1465
[13] Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Gopal, Ajay K.
Chen, Robert
Smith, Scott E.
Ansell, Stephen M.
Rosenblatt, Joseph D.
Savage, Kerry J.
Connors, Joseph M.
Engert, Andreas
Larsen, Emily K.
Chi, Xuedong
Sievers, Eric L.
Younes, Anas
[J]. BLOOD, 2015, 125 (08) : 1236 - 1243
[14] Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Green, Michael R.
Rodig, Scott
Juszczynski, Przemyslaw
Ouyang, Jing
Sinha, Papiya
O'Donnell, Evan
Neuberg, Donna
Shipp, Margaret A.
[J]. CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1611 - 1618
[15] RETRACTED: Activation of Hodgkin cells via the CD30 receptor induces autocrine secretion of interleukin-6 engaging the NF-kappa B transcription factor (Retracted article. See vol 93, pg 3573, 1999)
Gruss, HJ
Ulrich, D
Dower, SK
Herrmann, F
Brach, MA
[J]. BLOOD, 1996, 87 (06) : 2443 - 2449
[16] A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
Johnston, Patrick B.
Inwards, David J.
Colgan, Joseph P.
Laplant, Betsy R.
Kabat, Brian F.
Habermann, Thomas M.
Micallef, Ivana N.
Porrata, Luis F.
Ansell, Stephen M.
Reeder, Craig B.
Roy, Vivek
Witzig, Thomas E.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (05) : 320 - 324
[17] 20 YEARS OF MOPP THERAPY FOR HODGKINS-DISEASE
LONGO, DL
YOUNG, RC
WESLEY, M
HUBBARD, SM
DUFFEY, PL
JAFFE, ES
DEVITA, VT
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) : 1295 - 1306
[18] Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
Majhail, Navneet S.
Weisdorf, Daniel J.
Defor, Todd E.
Miller, Jeffrey S.
McGlave, Philip R.
Slungaard, Arne
Arora, Mukta
Ramsay, Norma K. C.
Orchard, Paul J.
MacMillan, Margaret L.
Burns, Linda J.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (10) : 1065 - 1072
[19] Moskowitz CH, 2014, 2014 ASH ANN M DEC S
[20] Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Okeley, Nicole M.
Miyamoto, Jamie B.
Zhang, Xinqun
Sanderson, Russell J.
Benjamin, Dennis R.
Sievers, Eric L.
Senter, Peter D.
Alley, Stephen C.
[J]. CLINICAL CANCER RESEARCH, 2010, 16 (03) : 888 - 897

← 1 2 3 4 →